PTC Therapeutics, Inc. (PTCT) Shares Sold by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board decreased its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 42.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,200 shares of the biopharmaceutical company’s stock after selling 17,400 shares during the quarter. Canada Pension Plan Investment Board owned 0.06% of PTC Therapeutics worth $464,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Fisher Asset Management LLC raised its position in PTC Therapeutics by 93.0% in the third quarter. Fisher Asset Management LLC now owns 173,045 shares of the biopharmaceutical company’s stock worth $3,463,000 after acquiring an additional 83,403 shares during the period. Public Employees Retirement System of Ohio bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at $142,000. Nomura Holdings Inc. raised its position in shares of PTC Therapeutics by 28.7% during the 2nd quarter. Nomura Holdings Inc. now owns 50,672 shares of the biopharmaceutical company’s stock valued at $928,000 after purchasing an additional 11,300 shares during the period. Voya Investment Management LLC raised its position in shares of PTC Therapeutics by 12.8% during the 2nd quarter. Voya Investment Management LLC now owns 16,459 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 1,866 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of PTC Therapeutics by 1.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 528,586 shares of the biopharmaceutical company’s stock valued at $9,689,000 after purchasing an additional 5,960 shares during the period. Hedge funds and other institutional investors own 86.18% of the company’s stock.

A number of analysts have issued reports on the stock. ValuEngine downgraded shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 7th. Barclays reissued a “hold” rating and issued a $22.00 price objective on shares of PTC Therapeutics in a research note on Friday, September 8th. Zacks Investment Research raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Wednesday, August 30th. J P Morgan Chase & Co cut shares of PTC Therapeutics from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $23.00 to $15.00 in a research note on Monday, October 9th. Finally, Citigroup reaffirmed a “buy” rating and set a $28.00 price target on shares of PTC Therapeutics in a research note on Wednesday, September 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $18.75.

PTC Therapeutics, Inc. (NASDAQ PTCT) traded up $0.64 during midday trading on Thursday, hitting $16.75. 782,891 shares of the company traded hands, compared to its average volume of 1,024,645. PTC Therapeutics, Inc. has a 1 year low of $8.12 and a 1 year high of $22.00. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.08 and a quick ratio of 2.97.

ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics, Inc. (PTCT) Shares Sold by Canada Pension Plan Investment Board” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/07/ptc-therapeutics-inc-ptct-shares-sold-by-canada-pension-plan-investment-board-updated-updated.html.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply